Your browser doesn't support javascript.
loading
Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.
Groza, Diana; Gehrig, Sebastian; Kudela, Pavol; Holcmann, Martin; Pirker, Christine; Dinhof, Carina; Schueffl, Hemma H; Sramko, Marek; Hoebart, Julia; Alioglu, Fatih; Grusch, Michael; Ogris, Manfred; Lubitz, Werner; Keppler, Bernhard K; Pashkunova-Martic, Irena; Kowol, Christian R; Sibilia, Maria; Berger, Walter; Heffeter, Petra.
Afiliação
  • Groza D; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Gehrig S; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria.
  • Kudela P; Laboratory of MacroMolecular Cancer Therapeutics ( MMCT), Center of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
  • Holcmann M; BIRD-C GmbH & CoKG, Vienna, Austria.
  • Pirker C; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Dinhof C; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Schueffl HH; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Sramko M; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Hoebart J; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria.
  • Alioglu F; BIRD-C GmbH & CoKG, Vienna, Austria.
  • Grusch M; Laboratory of MacroMolecular Cancer Therapeutics ( MMCT), Center of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
  • Ogris M; Laboratory of MacroMolecular Cancer Therapeutics ( MMCT), Center of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
  • Lubitz W; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Keppler BK; Laboratory of MacroMolecular Cancer Therapeutics ( MMCT), Center of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
  • Pashkunova-Martic I; BIRD-C GmbH & CoKG, Vienna, Austria.
  • Kowol CR; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
  • Sibilia M; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria.
  • Berger W; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
  • Heffeter P; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
Oncoimmunology ; 7(5): e1424676, 2018.
Article em En | MEDLINE | ID: mdl-29721389
ABSTRACT
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer mortality worldwide. At late stage of the disease CRC often shows (multiple) metastatic lesions in the peritoneal cavity which cannot be efficiently targeted by systemic chemotherapy. This is one major factor contributing to poor prognosis. Oxaliplatin is one of the most commonly used systemic treatment options for advanced CRC. However, drug resistance - often due to insufficient drug delivery - is still hampering successful treatment. The anticancer activity of oxaliplatin includes besides DNA damage also a strong immunogenic component. Consequently, the aim of this study was to investigate the effect of bacterial ghosts (BGs) as adjuvant immunostimulant on oxaliplatin efficacy. BGs are empty envelopes of gram-negative bacteria with a distinct immune-stimulatory potential. Indeed, we were able to show that the combination of BGs with oxaliplatin treatment had strong synergistic anticancer activity against the CT26 allograft, resulting in prolonged survival and even a complete remission in this murine model of CRC carcinomatosis. This synergistic effect was based on an enhanced induction of immunogenic cell death and activation of an efficient T-cell response leading to long-term anti-tumor memory effects. Taken together, co-application of BGs strengthens the immunogenic component of the oxaliplatin anticancer response and thus represents a promising natural immune-adjuvant to chemotherapy in advanced CRC.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article